open access

Vol 21, No 3 (2016)
Original research articles
Published online: 2016-05-01
Submitted: 2015-02-26
Get Citation

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Gustavo Arruda Viani, Bruno Tiago Rossi, Elton Suguikawa, Gisele Zuliani, Eduardo Jose Stefano
DOI: 10.1016/j.rpor.2015.12.003
·
Rep Pract Oncol Radiother 2016;21(3):162-167.

open access

Vol 21, No 3 (2016)
Original research articles
Published online: 2016-05-01
Submitted: 2015-02-26

Abstract

Aim

To report the treatment results of a retrospective cohort of prostate cancer patients treated with Hypo-RT with a high equivalent biological effective dose (BED).

Background

Hypofractionated radiotherapy (Hypo-RT) has gained popularity and interest in the treatment of prostate cancer. However, there are few experiences with adequate follow-up reporting treatment results using high equivalent dose with Hypo-RT.

Materials and methods

We assigned 149 men with low-, intermediate- and high-risk prostate cancer to receive Hypo-RT with a total dose of 69[[ce:hsp sp="0.25"/]]Gy/23 fractions. Late gastrointestinal (GI) and genitourinary (GU) toxicity were prospectively evaluated according to modified RTOG criteria. Biochemical no evidence of disease (bNED) was defined as the nadir prostate-specific antigen level plus 2[[ce:hsp sp="0.25"/]]ng/mL.

Results

The median follow-up was 53 months. For the entire cohort, the 5-year bNED rate was 94.6%, and for low-, intermediate- and high-risk patients the 5-year bNED was 100%, 96.4%, and 86% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.007), respectively. The 5-year overall survival rate was 92%. Only 1 patient died from the disease at 48 months after treatment, giving a 5-year cancer-specific survival of 98%. The worst grade ≥2 rate GI and GU toxicity was 13.4% and 14%, respectively. No grade >3 toxicity was observed. The presence of grade ≥2 GI and GU toxicity at the last follow-up was only 1.3% and 3%, respectively.

Conclusions

Hypo-RT (69[[ce:hsp sp="0.25"/]]Gy/23 fractions) with a high equivalent BED produces excellent rates of biochemical control for low, intermediate and high-risk prostate cancer. The long term GU and GI toxicity rates were considered low and acceptable.

Abstract

Aim

To report the treatment results of a retrospective cohort of prostate cancer patients treated with Hypo-RT with a high equivalent biological effective dose (BED).

Background

Hypofractionated radiotherapy (Hypo-RT) has gained popularity and interest in the treatment of prostate cancer. However, there are few experiences with adequate follow-up reporting treatment results using high equivalent dose with Hypo-RT.

Materials and methods

We assigned 149 men with low-, intermediate- and high-risk prostate cancer to receive Hypo-RT with a total dose of 69[[ce:hsp sp="0.25"/]]Gy/23 fractions. Late gastrointestinal (GI) and genitourinary (GU) toxicity were prospectively evaluated according to modified RTOG criteria. Biochemical no evidence of disease (bNED) was defined as the nadir prostate-specific antigen level plus 2[[ce:hsp sp="0.25"/]]ng/mL.

Results

The median follow-up was 53 months. For the entire cohort, the 5-year bNED rate was 94.6%, and for low-, intermediate- and high-risk patients the 5-year bNED was 100%, 96.4%, and 86% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.007), respectively. The 5-year overall survival rate was 92%. Only 1 patient died from the disease at 48 months after treatment, giving a 5-year cancer-specific survival of 98%. The worst grade ≥2 rate GI and GU toxicity was 13.4% and 14%, respectively. No grade >3 toxicity was observed. The presence of grade ≥2 GI and GU toxicity at the last follow-up was only 1.3% and 3%, respectively.

Conclusions

Hypo-RT (69[[ce:hsp sp="0.25"/]]Gy/23 fractions) with a high equivalent BED produces excellent rates of biochemical control for low, intermediate and high-risk prostate cancer. The long term GU and GI toxicity rates were considered low and acceptable.

Get Citation

Keywords

3D-CRT; Late toxicity; Biochemical control; Outcomes

About this article
Title

Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 21, No 3 (2016)

Pages

162-167

Published online

2016-05-01

DOI

10.1016/j.rpor.2015.12.003

Bibliographic record

Rep Pract Oncol Radiother 2016;21(3):162-167.

Keywords

3D-CRT
Late toxicity
Biochemical control
Outcomes

Authors

Gustavo Arruda Viani
Bruno Tiago Rossi
Elton Suguikawa
Gisele Zuliani
Eduardo Jose Stefano

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl